Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRNDM-02
- Development stage
- Preclinical
- Lead developer
- Sirius Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
SRNDM-02 is a preclinical small interfering RNA (siRNA) therapeutic candidate being developed by Sirius Therapeutics (also known as Sirius Natural) for the treatment of cardiometabolic diseases. As part of Sirius's broader pipeline of RNA-based therapies, SRNDM-02 utilizes the company's proprietary delivery platforms designed to target specific tissues such as the liver, adipose tissue, heart, kidney, or the central nervous system (CNS). The drug functions through the RNA interference (RNAi) pathway to silence a specific gene involved in the pathogenesis of cardiometabolic disorders. While the molecular target of SRNDM-02 remains undisclosed by the developer, the program is currently in the pre-clinical/IND-enabling stage of development.
- Other names
- SRNDM-02-Sirius Natural-siRNA-Liver, Adipose, Heart, Kidney, or CNS targeted delivery (company's siRNA delivery routes)-Cardiometabolic disease
Beyond the preview
Go deeper on SRNDM-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRNDM-02.